Description

Simple

Clinical

Overview

Danoprevir has been used in trials studying the treatment of Hepatitis C, Chronic.

Pharmacology

Indication

Information currently not available.

Pharmacodynamic

Information currently not available.

Mechanism of action

Danoprevir is a NS3/4A protease inhibitor. The HCV NS3/4A protease is an attractive drug target because of its potential involvement in viral replication and suppressive effects on host response to viral infection. Inhibitors of the HCV protease, such as Danoprevir, represent a promising new class o... Read more

Absorption

Information currently not available.

Protein binding

Information currently not available.

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

Information currently not available.

Route of elimination

Information currently not available.

Toxicity

Information currently not available.

Adverse Effects

Contraindications

Information currently not available.

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with Danoprevir
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
(R)-warfarin
The serum concentration of (R)-warfarin can be increased when it is combined with Danoprevir.
(S)-Warfarin
The serum concentration of (S)-Warfarin can be increased when it is combined with Danoprevir.
4-hydroxycoumarin
The metabolism of 4-hydroxycoumarin can be decreased when combined with Danoprevir.
9-aminocamptothecin
The metabolism of 9-aminocamptothecin can be decreased when combined with Danoprevir.
Abemaciclib
The metabolism of Abemaciclib can be decreased when combined with Danoprevir.
Acenocoumarol
The serum concentration of Acenocoumarol can be increased when it is combined with Danoprevir.
Albendazole
The metabolism of Albendazole can be decreased when combined with Danoprevir.
Aldosterone
The metabolism of Aldosterone can be decreased when combined with Danoprevir.
Alfentanil
The metabolism of Alfentanil can be decreased when combined with Danoprevir.
Alfuzosin
The metabolism of Alfuzosin can be decreased when combined with Danoprevir.
Allylestrenol
The metabolism of Allylestrenol can be decreased when combined with Danoprevir.
Almotriptan
The metabolism of Almotriptan can be decreased when combined with Danoprevir.
Alpelisib
The metabolism of Alpelisib can be decreased when combined with Danoprevir.
Alprazolam
The metabolism of Alprazolam can be decreased when combined with Danoprevir.
Aminophylline
The metabolism of Aminophylline can be decreased when combined with Danoprevir.
Amiodarone
The metabolism of Amiodarone can be decreased when combined with Danoprevir.
Amlodipine
The metabolism of Amlodipine can be decreased when combined with Danoprevir.
Apalutamide
The metabolism of Apalutamide can be decreased when combined with Danoprevir.
Aripiprazole
The metabolism of Aripiprazole can be decreased when combined with Danoprevir.
Aripiprazole lauroxil
The metabolism of Aripiprazole lauroxil can be decreased when combined with Danoprevir.
1 References
  1. 1 . He Y, King MS, Kempf DJ, Lu L, Lim HB, Krishnan P, Kati W, Middleton T, Molla A: Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system. Antimicrob Agents Chemother. 2008 Mar;52(3):1101-10. Epub 2007 Dec 17.PubMed: 18086851